Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Shares Outstanding (Diluted Average) (2016 - 2025)

Haemonetics (HAE) has 17 years of Shares Outstanding (Diluted Average) data on record, last reported at $47.7 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 6.8% year-over-year to $47.7 million; the TTM value through Dec 2025 reached $47.7 million, down 6.8%, while the annual FY2025 figure was $50.7 million, 1.3% down from the prior year.
  • Shares Outstanding (Diluted Average) reached $47.7 million in Q4 2025 per HAE's latest filing, down from $48.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $51.7 million in Q3 2022 and bottomed at $47.7 million in Q4 2025.
  • Average Shares Outstanding (Diluted Average) over 5 years is $50.8 million, with a median of $51.3 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 1.46% in 2022, then decreased 6.8% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $51.5 million in 2021, then decreased by 0.46% to $51.2 million in 2022, then grew by 0.34% to $51.4 million in 2023, then dropped by 0.48% to $51.1 million in 2024, then dropped by 6.8% to $47.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $47.7 million in Q4 2025, $48.0 million in Q3 2025, and $48.4 million in Q2 2025.